Drug firms argue against $1.2B Arkansas judgment

(AP)—A lawyer for two drug companies told the Arkansas Supreme Court that the state improperly relied on federal regulations in a lawsuit that resulted in a $1.2 billion award over the companies' marketing of an antipsychotics drug.

The state's countered during Thursday's hearing before the high court that Johnson & Johnson and a subsidiary were properly penalized for improper marketing of the drug Risperdal.

A Pulaski County jury ruled against the companies in 2012.

The companies also argued that the state brought the case under a Medicaid fraud law when there were no indications of improper reimbursements.

Sixty-five legislators filed a friend of the court brief saying the law was properly applied.

Johnson & Johnson separately agreed to a $2.2 billion federal settlement on similar claims.

Related Stories

Ark. judge affirms $181 million in legal fees

date Feb 01, 2013

(AP)—An Arkansas judge says Johnson & Johnson must pay $181 million in fees to attorneys who successfully argued that the pharmaceutical company committed Medicaid fraud in the marketing of its antipsychotic drug Risperdal.

Report: J&J will pay $2.2B in Risperdal settlement

date Jul 20, 2012

(AP) — Johnson & Johnson has agreed to pay as much as $2.2 billion to resolve an investigation into its marketing of the anti-psychotic drug Risperdal, according to a published report.

Authorities in US sue Novartis in kickback scheme

date Jan 09, 2014

Novartis Pharmaceuticals Corp. paid kickbacks to a specialty pharmacy in exchange for recommending refills of a blood transfusion drug it produces, according to an amended complaint filed Wednesday in a civil case brought ...

High court weighs drug companies' generics policy

date Mar 25, 2013

(AP)—The Supreme Court is struggling with whether it should stop pharmaceutical corporations from paying generic drug competitors to delay releasing their cheaper versions of brand-name drugs.

Recommended for you

Mylan rebuffs Teva again; calls bid low, insincere

date 2 hours ago

Generic drug company Mylan rejected for the second time Monday a $40.1 billion takeover offer from Israeli pharmaceutical power Teva, just days after Mylan's own bid for rival Perrigo was rebuffed.

Rising antibiotic shortages raise concerns about patient care

date Apr 23, 2015

Shortages of key antibiotics, including gold-standard therapies and drugs used to treat highly resistant infections, are on the rise, according to a new study of shortages from 2001 to 2013 published in Clinical Infectious Di ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.